Abstract
Purpose :
To characterize the optical coherence tomography (OCT) features and long-term outcomes of neovascular age related macular degeneration(nAMD) patients with non-subfoveal choroidal neovascularisation(CNV) with visual acuity(VA) > 20/40.
Methods :
Retrospective analysis of 74 eyes from 69 patients with a diagnosis of nAMD with non-subfoveal CNV and VA >20/40 with three year follow-up was done.. Exclusion criteria included eyes with VA≤20/40, eyes with subfoveal CNV, and lack of imaging data. Various OCT imaging biomarkers analyzed at baseline and every 6 months for 3 years.Multivariate logistic regression was used to analyze associations between OCT imaging parameters and visual prognosis at 3-year follow-up.
Results :
A total of 17 eyes (22.9%) of 17 patients had non-subfoveal CNV. Baseline mean logMAR VA was 0.102±0.06(Snellen’s equivalent 20/25) and 0.309±0.53 (Snellen’s equivalent 20/40) at 3 years follow-up (p=0.12). Only 3 eyes (17.6%) lost more than 3 Snellen lines during anti-VEGF monotherapy. Mean baseline central macular thickness (CMT) was 269.61±32.68 and 254.41±33.27 at 3 year follow up (p=0.1884). Mean CNV length (microns) was 766.24±296.12 at baseline and 1286.02±849.46 at 3 year follow up (p=0.02). Mean subfoveal choroidal thickness (SFCT) (microns) at baseline was 181.88± 65.82 and 170.02±70.25 at 3 year follow-up (p=0.61). Over 3 years, 10 eyes had expansion of CNV location (58.8%), 8 (47%) of them expanded subfoveally. Mean number of injections was 4.29±3.73, 3.64±3.35 and 3.64±3.56 in 1st, 2nd and 3rd year respectively. Average maximum treatment-free interval (months) was 6±4.35, 6.35±4.1,and 6.17±4.54 months in 1st, 2nd, and 3rd year respectively.No association was found between baseline features with VA at 3 years follow-up (p>0.05).
Conclusions :
In nAMD eyes with non-subfoveal CNV, mean VA at baseline was 20/25 and 82.3% had improved or maintained VA at 3 year follow-up. In these eyes, a close follow-up and appropriate management is required to preserve vision.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.